These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24187041)

  • 1. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.
    Fourati S; Flandre P; Calin R; Carcelain G; Soulie C; Lambert-Niclot S; Maiga A; Ait-Arkoub Z; Tubiana R; Valantin MA; Autran B; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Mar; 69(3):753-6. PubMed ID: 24187041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
    J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
    Torres-Cornejo A; Benmarzouk-Hidalgo OJ; Gutiérrez-Valencia A; Pérez-Romero P; Martín-Peña R; Ruiz-Valderas R; Viciana P; Lopez-Cortes LF
    AIDS; 2014 Jan; 28(2):201-8. PubMed ID: 24361681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
    Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
    J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.
    Laanani M; Ghosn J; Essat A; Melard A; Seng R; Gousset M; Panjo H; Mortier E; Girard PM; Goujard C; Meyer L; Rouzioux C;
    Clin Infect Dis; 2015 Jun; 60(11):1715-21. PubMed ID: 25737374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.
    Burgard M; Izopet J; Dumon B; Tamalet C; Descamps D; Ruffault A; Vabret A; Bargues G; Mouroux M; Pellegrin I; Ivanoff S; Guisthau O; Calvez V; Seigneurin JM; Rouzioux C
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1939-47. PubMed ID: 11153076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients.
    Burgard M; Boufassa F; Viard JP; Garrigue I; Ruffault A; Izopet J; Vabret A; Descamps D; Colson P; Seigneurin JM; Rouzioux C;
    AIDS; 2009 Oct; 23(16):2165-71. PubMed ID: 19657270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.
    Eriksson S; Graf EH; Dahl V; Strain MC; Yukl SA; Lysenko ES; Bosch RJ; Lai J; Chioma S; Emad F; Abdel-Mohsen M; Hoh R; Hecht F; Hunt P; Somsouk M; Wong J; Johnston R; Siliciano RF; Richman DD; O'Doherty U; Palmer S; Deeks SG; Siliciano JD
    PLoS Pathog; 2013 Feb; 9(2):e1003174. PubMed ID: 23459007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Few modifications of the Cobas Amplicor HIV Monitor 1.5 test allow reliable quantitation of HIV-1 proviral load in peripheral blood mononuclear cells.
    Lillo FB; Grasso MA; Lodini S; Bellotti MG; Colucci G
    J Virol Methods; 2004 Sep; 120(2):201-5. PubMed ID: 15288963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.
    Assoumou L; Weiss L; Piketty C; Burgard M; Melard A; Girard PM; Rouzioux C; Costagliola D;
    AIDS; 2015 Sep; 29(15):2003-7. PubMed ID: 26355572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.
    Tincati C; Biasin M; Bandera A; Violin M; Marchetti G; Piacentini L; Vago GL; Balotta C; Moroni M; Franzetti F; Clerici M; Gori A
    Antivir Ther; 2009; 14(3):321-30. PubMed ID: 19474466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
    Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
    J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
    Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
    J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.
    Kiselinova M; Geretti AM; Malatinkova E; Vervisch K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
    J Antimicrob Chemother; 2015 Dec; 70(12):3311-6. PubMed ID: 26324076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
    Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
    J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.